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Abstract
Background: Monitoring the effectiveness of global antiretroviral therapy scale-up efforts in resource-limited settings is a
global health priority, but is complicated by high rates of losses to follow-up after treatment initiation. Determining
definitive outcomes of these lost patients, and the effects of losses to follow-up on estimates of survival and risk factors for
death after HAART, are key to monitoring the effectiveness of global HAART scale-up efforts.
Methodology/Principal Findings: A cohort study comparing clinical outcomes and risk factors for death after HAART
initiation as reported before and after tracing of patients lost to follow-up was conducted in Botswana’s National
Antiretroviral Therapy Program. 410 HIV-infected adults consecutively presenting for HAART were evaluated. The main
outcome measures were death or loss to follow-up within the first year after HAART initiation. Of 68 patients initially
categorized as lost, over half (58.8%) were confirmed dead after tracing. Patient tracing resulted in reporting of significantly
lower survival rates when death was used as the outcome and losses to follow-up were censored [1-year Kaplan Meier
survival estimate 0.92 (95% confidence interval, 0.88–0.94 before tracing and 0.83 (95% confidence interval, 0.79–0.86) after
tracing, log rank P,0.001]. In addition, a significantly increased risk of death after HAART among men [adjusted hazard ratio
1.74 (95% confidence interval, 1.05–2.87)] would have been missed had patients not been traced [adjusted hazard ratio 1.41
(95% confidence interval, 0.65–3.05)].
Conclusions/Significance: Due to high rates of death among patients lost to follow-up after HAART, survival rates may be
inaccurate and important risk factors for death may be missed if patients are not actively traced. Patient tracing and uniform
reporting of outcomes after HAART are needed to enable accurate monitoring of global HAART scale-up efforts.
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Introduction
As of 2005 an estimated 1.3 million people were receiving
highly active antiretroviral therapy (HAART) in low- and middle-
income countries[1]. As HAART scale-up has progressed, major
challenges inherent in following large numbers of patients in
resource-limited settings have emerged[2]. One problem relates to
keeping patients in care, and published rates of loss to follow-up
after HAART initiation in antiretroviral therapy programs in sub-
Saharan Africa have varied widely[3], from approximately 0[4] to
39%[5]. Furthermore, while patient tracing (e.g., phoning or
visiting patients when they do not present to clinic) is ideal it is not
always feasible and passive follow-up, where patients who miss
visits are not traced, is common.
From a public health perspective, the most important measure
of an antiretroviral therapy program’s effectiveness is survival after
HAART. However, losses to follow-up may threaten the validity of
analyses of survival if the proportion of patients dying after
HAART is high and only known deaths are counted as events.
Furthermore, censoring, or not counting, patients lost to follow-up
as having died, while standard, could lead not only to inaccurate
estimates of survival but to biased estimates of risk factors for death
as well. The latter issue, called informative censoring, may occur in
survival analyses when patients who are lost to follow-up are both
censored and at high risk of having died[6]. Since many cohort
studies of survival after HAART have had substantial rates of
losses to follow-up after HAART[3], and since both monitoring
antiretroviral therapy scale-up efforts and improving these efforts
depends on accurate reporting of survival rates and risk factors for
death, evaluating and quantifying these issues is of global health
importance. To investigate this further, we analyzed how
outcomes and risk factors for death after HAART initiation in a
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reported in two scenarios: one before and one after patient tracing.
Methods
Study Design
This was a cohort study comparing treatment outcomes and risk
factors for death within the first 12 months after HAART
initiation as reported before and after patient tracing during early
rapid scale-up within Botswana’s National Antiretroviral Therapy
Program (called Masa, which is Setswana for ‘‘New Dawn’’). Since
determining outcomes on patients within a clinic is conceivably
most difficult during initial rapid scale-up, and since Botswana’s
National Antiretroviral Therapy Program officially began in 2002,
we studied patients presenting for HAART soon after the clinic
began dispensing HAART.
Study Setting
This study was set at one of the main public clinics of Masa, the
Infectious Disease Care Clinic (IDCC), in Gaborone, Botswana.
The IDCC in Gaborone was the first clinic of Masa to begin
providing HAART to patients with AIDS and, during the study
period, was the main site of rapid HAART scale-up efforts in the
country. Thus, early in Botswana’s scale-up effort, the IDCC
encountered challenges with respect to providing HIV care to an
increasingly large number of individuals with limited resources,
and therefore was considered an appropriate site in which to
perform the study.
Patients presenting to Masa for care routinely have data on a
patient or patient contact’s phone number and information
regarding place of current residence collected at the time of
registration. In Masa, patients required either a CD4 count of less
than 200 cells/mm
3 or an opportunistic infection to start HAART.
In Masa at the time the data were collected, CD4 counts were the
primary variable used to time initiation of HAART and thus
World Health Organization and Center for Disease Control and
Prevention (CDC) staging were usually unavailable for analysis.
Tuberculosis in Botswana is considered present if the patient has a
history of a positive acid fast bacilli smear from any site or has a
negative sputum smear and a positive culture for M. tuberculosis or
highly suspicious radiological features or clinical findings of
tuberculosis as determined by a physician [7]. First line therapy
in Masa during the study consisted of fixed dose combination
zidovudine and lamivudine (CombivirH) plus efavirenz (SustivaH)
or nevirapine (ViramuneH). Patients were seen at a pretreatment
visit and adherence counseling and standard baseline tests were
done including CD4 count (EPICS, Beckman Coulter), plasma
HIV-1 RNA level (Amplicor HIV-1 Monitor Assay), and complete
blood count. Patients then initiated HAART and were followed
via clinical visits approximately every 3 months and medications
were filled on a monthly basis, most often coinciding with a clinic
visit, when possible.
Study Subjects
We retrospectively identified all HIV-infected adults ($18 years)
consecutively presenting to the IDCC for care and initiating
HAART during the study period of interest using the Microsoft
Access
 database which was designed for use in clinical care at the
IDCC during this time. Due to the implementation of a new
national electronic medical record in March 2004, which resulted
in cessation of use of the Access database, and because we wanted
each patient to have at least 6 months of potential follow-up,
patients were eligible if they registered at least 7 months prior to
March 2004 (the extra month was included to give patients time to
register and, two to four weeks later, initiate HAART). Thus,
patients registering at the IDCC between February 2003 and
August 2003 and initiating HAART were eligible for inclusion in
the study.
Data Collection
After identification of eligible study subjects, we used the IDCC
paper chart, on which primary caregiver notes are written, and the
IDCC electronic database in use at the time, which also contains
clinical notes as well as information on dates of patient clinic and
hospital visits and pharmacy data, to retrospectively describe
patient characteristics. Providers record clinical data in these
sources during patient visits. Tuberculosis was considered present
if the paper or electronic records noted this condition or if the
patient was on anti-tubercular therapy at the time of HAART
initiation (as indicated by either the clinical or pharmacy record).
Information from these sources was later abstracted and entered
into a study-specific Microsoft Access database.
Each patient in the cohort was initially classified as alive, lost, or
dead using this retrospective data collection process. Specifically, a
patient was considered alive and in care if they were in between
visits and were known to have refilled their HAART at the
pharmacy within the prior 30 days, and as dead if their deaths
were recorded anywhere in the clinical record (including records
of the adjacent tertiary care hospital). Before tracing, a patient was
classified as lost if their last contact with the clinic (including the
pharmacy) was greater than 30 days past their last scheduled visit.
Patients who were lost to follow-up at this stage were
prospectively traced. Patient tracing involved phone calls and, if
necessary, home visits. Maps to patients’ houses were not routinely
collected at the time of registration. Specifically, patients initially
classified as lost to follow-up were searched for by first calling the
available contact number provided to the clinic at the time of
registration and, if that did not result in useful contact, calling
patient contacts, also provided at registration. If after 3 phone calls
on variable times on separate days the patient’s status could not be
ascertained, a Setswana-speaking study nurse from the IDCC
made a home visit to check with either the patient or his family.
Patient transfers to other clinics were recorded in the clinic
database and were ascertained if present. If the phone calls and
home visits neither confirmed that the patient was alive nor
confirmed their death, the patient remained classified as lost to
follow-up. Dates of death were obtained from the paper or
electronic clinical record or, if not in that source, from patient
contacts. Patients who were alive and in care and those who were
lost to follow-up were classified as having their respective outcomes
at the date of the last clinic visit. Due to the retrospective nature of
patient identification, patient tracing was performed at variable
time intervals after a patient’s last clinic visit.
Statistical Analysis
Continuous variables were compared using t tests or rank sum
tests after testing the normality of the distribution using the
Shapiro-Wilk test. Chi-square tests were used to compare
categorical variables.
Date of HAART initiation and date of outcome were used as
the start and end point of follow-up time, respectively. Patients
who were alive and in care and patients who were lost to follow-up
were censored as of the date of their last clinic visit. Kaplan-Meier
plots were used to present 1-year survival estimates before and
after patient tracing. Risk factors for death before and after patient
tracing were evaluated using Cox proportional hazards models
after testing the validity of the proportional hazards assump-
tion[6,8]. Factors where the 95% confidence interval of the point
Survival after HAART
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unadjusted analysis were retained and evaluated in a multivariable
model. However, in order to evaluate if the inclusion of possible
confounders not meeting this criterion in the analysis affected the
study’s findings, we also evaluated the results after forcing
variables plausibly associated with survival in the multivariable
model [9]. Collinearity between potential risk factors was assessed
by examining the standard errors for the hazard ratios when the
multivariable Cox regression model was fitted. Bias was considered
present if the point-estimates of the relative hazards produced
before and after tracing differed by 20% or more[6]. Analyses
were conducted using STATA version 8.2 (Intercooled).
The Health Research Development Council of the Botswana
Ministry of Health and the Institutional Review Board of the
University of Pennsylvania approved this study. Since tracing in
the case of a patient becoming lost to follow-up is discussed with
patients initiating HAART in the IDCC, a waiver of informed
consent was obtained for the study.
Results
Patient characteristics
Between February 5
th and July 29
th, 2003, a total of 524 patients
presented to the IDCC for evaluation to start HAART. Of these,
410 (78%) initiated HAART during the study period and therefore
were included in subsequent analyses. Of the 114 who were not
included in the study, 38 (33%) were transferred to other clinics
prior to HAART initiation, 32 (28%) had CD4 counts .200 cells/
mm
3 and no opportunistic infections and therefore did not qualify
for HAART, 17 (15%) died shortly after registration and prior to
initiating HAART, 12 patients (11%) initiated HAART but would
not have had at least 6 months of follow-up and were therefore
excluded, 12 (11%) were lost to follow-up shortly after registration
and prior to initiating HAART, and 3 (3%) patients had
tuberculosis and CD4 counts .500 cells/mm
3 and therefore
had HAART delayed.
The baseline characteristics of the 410 patients initiating
HAART are given in Table 1. Most patients [339 of 410,
(83%)] initiated regimens containing fixed-dose zidovudine and
lamivudine plus a non-nucleoside reverse transcriptase inhibitor.
359 of 410 (88%) were treatment naı ¨ve at the time of initiation.
Analysis of outcomes before and after patient tracing
410 patients contributed 317 patient-years of follow-up; the
median duration of follow-up among patients on HAART was 44
weeks (inter-quartile range (IQR), 37–49). Of the 68 patients who
were originally lost to follow-up, 65 (96%) were called and 19
(28%) were visited. Patient tracing significantly increased the
number of reported deaths [29 of 410 (7.1%) vs. 69 of 410 (16.8%);
P,0.001 for difference in proportion reported dead]. Of the 68
patients initially categorized as lost, over half (58.8%) were
confirmed dead after tracing (Table 2), and 57.9% (40 of 69) of all
deaths after HAART were initially categorized as lost to follow-up.
The median survival time after HAART for those who were
characterized as lost before tracing and then confirmed dead after
tracing was 47 days (IQR, 24–98 days). Furthermore, the median
pre-treatment CD4 cell count of the 22 patients who remained lost
to follow-up after tracing was significantly lower compared to pre-
treatment CD4 counts of patients remaining alive and in care [37
cells/mm
3 (IQR 17–77) vs. 98 (IQR 38–158), rank sum
P=0.009]. The 1-year Kaplan-Meier survival estimates before
and after tracing are shown in Figure 1. Patient tracing resulted in
reporting of a significantly lower estimate of survival than was
observed before tracing [log rank P,0.001, Figure 1]. This effect
can be attributed to an increased number of ascertained deaths in
the setting of an unchanged number of patients at risk after tracing
(Table 2).
Risk factors for death after HAART
All variables in Table 1 were analyzed in univariate analysis.
Using outcomes obtained by tracing, patients who died at any time
during the period of study were significantly more likely to be male
[36 of 166 (21.7%) vs. 33 of 244 (13.5%); P=0.03] and to have
lower baseline CD4 counts [median 33.5 (IQR 15–75) vs 94.0
cells/mm
3 (IQR 38–155), P,0.001] and lower baseline hemoglo-
bin levels [median 9.8 gm/dL (IQR 7.9–11.1) vs 10.4 gm/dL
(IQR 9.1–11.9), P=0.002]. Men had lower baseline CD4 counts
than women [median 68 (IQR 29–116) vs. 90 (IQR 32–160) cells/
mm
3, P=0.03)] but higher baseline hemoglobin levels [median 9.9
(IQR 8.6–11.1) vs. 11.1 gm/dL (IQR 9.5–12.6), P ,0.001] and
similar plasma viral loads [5.7 (IQR) 5.2–5.9) vs. 5.6 (IQR 5.1 vs.
5.9) log10 copies/mL, P =0.37]. Unadjusted hazard ratios for
these variables are presented in Table 3. Categorization of
baseline CD4 count and baseline hemoglobin levels as shown in
Table 3 is based on the finding that risk did not vary substantially
across finer categorization schemes (data not shown). Adjusted
hazard ratios (AHR), controlling for male sex, baseline CD4
count, and baseline hemoglobin level (which were independently
associated with death) as well as baseline viral load and age (which
did not meet our criteria for potential confounders but which but
which are plausibly associated with survival and were therefore
forced into the model) are also presented in Table 3.
Bias towards no association was present for all variables tested
when outcomes observed prior to tracing were analyzed, and this
effect was strongest when determining the AHR of death for a
baseline CD4 count of 50–99 compared to $100 cells/mm
3 (AHR
of 1.81 before tracing compared to 2.51 after tracing, or a 39%
change) and for male sex (AHR of 1.41 before tracing compared to
1.74 after tracing, or a 23% change) (Table 3).
Table 1. Baseline characteristics of patients prior to initiating
HAART in the IDCC, Gaborone, Botswana (N=410)
Age: years, mean (range) 37 (19–74)
Female sex, n (%) 244 (60%)
Weight: kg, median (IQR) 52 (45–60)
ARV naı ¨ve, n (%) 359 (88%)
CD4 count, median cells/mm
3 (IQR) 81 (31–145)
Viral load, median log10 copies/mL plasma (IQR) 5.67 (5.11–5.88)
Hemoglobin level, g/dL (IQR) 10.3 (8.9–11.8)
Tuberculosis, n (%) 133 (32%)
Initial HAART regimens
zidovudine+lamivudine+efavirenz 171 (42%)
zidovudine+lamivudine+nevirapine 168 (41%)
lamivudine+stavudine+efavirenz 24 (6%)
lamivudine+stavudine+nevirapine 23 (5%)
didanosine+stavudine+efavirenz 3 (1%)
didanosince+stavudince+nevirapine 8 (2%)
Other 14 (3%)
IQR = inter-quartile range; ARV = antiretroviral therapy; HAART = highly
active antiretroviral therapy
doi:10.1371/journal.pone.0001725.t001
Survival after HAART
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This analysis from a large public antiretroviral therapy program
in sub-Saharan Africa documents a substantial death rate among
patients lost to follow-up soon after initiating HAART, and
illustrates how deaths among patients lost to follow-up can result in
both inaccurate estimates of survival and biased estimates of risk
factors for death after HAART initiation.
From a clinical perspective, the fact that nearly 60% of those
initially considered lost to follow-up prior to tracing were later
found to have died suggests that interventions designed to decrease
mortality after HAART initiation will need to include methods to
identify, locate, diagnose and, if possible, treat incident illnesses in
those who miss even a single clinic visit. Given the very short
survival after HAART initiation among patients initially catego-
rized as lost but who were eventually confirmed dead (i.e., 42
days), this finding also suggests that such interventions should be
able to identify these patients rapidly. From a public health
perspective, these results suggest that death rates after HAART
initiation within antiretroviral therapy clinics may be systemati-
cally underestimated if losses to follow-up are substantial and
patients with very low pre-treatment CD4 counts are presenting
for care. For example, in this study, nearly 60% of all deaths
within the first year would not have been detected unless patient
tracing was performed. Thus, precise estimates of the actual
effectiveness of global antiretroviral scale-up efforts will be difficult
if not impossible to obtain unless patient tracing is undertaken, at
least among those on whom outcomes are formally reported.
Since limited data on definitive outcomes among patients lost to
follow-up after HAART initiation in sub-Saharan Africa exist, it is
difficult to assess the scope of this problem. In particular, although
patient tracing has been associated with lower survival estimates
among HIV-infected patients not on HAART[10], little is known
about actual outcomes among patients who have initiated
HAART. However, a recent report from four public sector
antiretroviral therapy clinics in northern Malawi during 2004–
2006 used patient tracing (including home visits) and found that
50% of those not attending clinic for 3 or more months had died,
indicating that high rates of death among patients who do not
return to clinic after HAART initiation are also currently being
found in other settings[11]. Since only 5% of all patients starting
HAART in the Malawi report were categorized as lost to follow-
up, however, the effects of deaths among those initially considered
lost on overall survival estimates would likely have been less
pronounced than was shown in this study, where the initial loss to
follow-up rate was approximately 17%[11]. This study extends
findings from the Malawi study by documenting the effect of
undetected deaths on overall survival estimates, and suggests that
Figure 1. Kaplan-Meier curve 52-week survival estimates before and after patient tracing, IDCC, Gaborone, Botswana. Losses to
follow-up are censored. Log rank P ,0.001.
doi:10.1371/journal.pone.0001725.g001
Table 2. Patient outcomes before and after tracing in the Infectious Disease Care Clinic, Gaborone, Botswana.
Outcome Before tracing (95% CI) After tracing (95% CI) P value*
Lost: n, % 68 (16.6%, 13.1–20.5) 22 (5.4%, 3.4–8.0) ,0.001
Dead: n, % 29 (7.1%, 4.7–10.0) 69 (16.8%, 13.3–20.8) ,0.001
Alive on HAART: n, % 313 (76.3%, 71.2–80.3) 319 (77.8%, 73.5–81.7)
{ .0.5
N=410
*P value is for difference in proportion of patients categorized as lost, dead, or on HAART according to two different methods of follow-up.
{Tracing revealed that 6 patients originally categorized as lost were still on HAART in the IDCC but had different medical record numbers and were not included in the
pharmacy database.
doi:10.1371/journal.pone.0001725.t002
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follow-up rate and the proportion of deaths among these
individuals. Since losses to follow-up in several large public
antiretroviral therapy clinics in Zambia (21%)[12], South Africa
(14%), Cote d’Ivoire (11%)[13], additional settings in Malawi
(7%)[14,15], Uganda (11%)[16], Kenya (15–25%)[17,18] and in
the Antiretroviral Therapy in Lower Income Countries (ART-
LINC) collaboration (19% among clinics not performing trac-
ing)[19] have been substantial, underestimation of deaths after
HAART initiation in many reports from the region could be
common.
Thefindingofsubstantial deathratesamongpatientswhoarelost
to follow-up also suggests that death rates after HAART initiation in
the developing world may be higher than previously suspected. The
ART-LINC study comparing outcomes after antiretroviral therapy
initiation in low and high income countries excluded clinics that did
not trace patients from survival analyses, found greater ascertain-
ment of deaths in developed countries, and documented higher
rates of losses to follow-up in developing countries[19]. Thus, while
inability to ascertain outcomes among patients lost to follow-up
could bias mortality estimates in both the ART-LINC and the
ART-CC data, higher rates of losses to follow-up in the ART-LINC
patients creates the possibility that deaths may have been
underestimated to a greater degree in this group.
This study differs from several previous reports in that we
performed prospective data collection on patients consecutively
initiating HAART at a large antiretroviral therapy program in
sub-Saharan Africa specifically to determine definitive outcomes
on patients who were initially considered lost to follow-up and to
compare survival estimates and risk factors for death before and
after active tracing was performed. Although the ART-LINC
collaboration documented higher rates of loss to follow-up among
clinics which did not trace patients[19], this analysis compared one
type of clinic to another rather than comparing outcomes before
and after tracing within a single group of patients. Furthermore,
while the study from Malawi confirmed a high rate of death
among patients who were lost[11], the effect of these deaths on
estimates of overall outcomes was not evaluated.
Another difference of this study from the Malawi study[11] is
that we analyzed the effects of losses to follow-up on reported risk
factors for death after HAART initiation. The tendency of losses
to follow-up to bias analyses of risk factors for death, as was
documented here for both baseline CD4 counts and male sex, is
concerning. While this is less likely to be a problem when
analyzing factors with strong biologic associations with survival
(like baseline CD4 counts), factors with smaller strengths of
association but with considerable public health impact may
conceivably be missed if losses to follow-up are censored. Male
sex is one example of such a factor. Whereas men have been
shown to be at increased risk of death or loss to follow-up after
HAART in this study and in several other large co-
horts[12,14,18,20], numerous other studies have not found this
association[21,22], including a large multinational analysis from
ART-LINC[19]. This finding should be investigated prospectively.
More broadly, a critical component of improving outcomes in
global antiretroviral therapy scale-up efforts is accurate identifica-
tion of groups at high risk of death after HAART initiation, and
these data indicate the importance of patient tracing in such
investigations.
This study has several important limitations. First, reasons for
losses to follow-up after HAART initiation were not formally
explored, and thus it is impossible to determine from these data the
precise interventions capable of keeping patients alive and in care.
In particular, we had limited data on social or behavioral factors
that may influence adherence[23] to HAART in this setting. Verbal
autopsies, which were not performed, may have enhanced the
analysis by providing insights into likely causes of death, as has been
shown in other sites[22]. Furthermore, while a recent report from
Zambia suggested that retention rates among patients lost to follow-
up were low despite multiple calls and visits[12], the effectiveness of
such efforts needs further prospective evaluation. Another limitation
relatestothe fact that approximately5%ofpatientsremained lostto
follow-up despite patient tracing. The association between lower
baseline CD4 count and being lost to follow-up among patients
remaining lost after tracing, which concurs with findings from a
large French database[24] and from ART-LINC cohorts not
Table 3. Hazard ratios for death before and after tracing after initiation of HAART in the IDCC, Gaborone, Botswana.
Before tracing After tracing
Unadjusted HR (95% CI) Adjusted HR (95% CI) Unadjusted HR (95% CI) Adjusted HR (95% CI)
Characteristic
Sex
Female 1 1
Male 1.40 (0.67–2.95) 1.41 (0.65–3.05)* 1.81 (1.11–2.93) 1.74 (1.05–2.87) *
Baseline CD4 count, cells/mm
3
$100 1 1
50–99 2.01 (0.61–6.60) 1.81 (0.55–6.04)
{ 2.80 (1.30–6.06) 2.51 (1.15–5.48)
{
,50 4.06 (1.60–10.29) 3.49 (1.33–9.17) 4.60 (2.41–8.77) 3.86 (1.98–7.53)
Baseline hemoglobin, gm/dL
$9.0 1 1
,9.0 1.93 (1.17–3.20) 1.76 (1.05–2.96)
Y 1.61 (0.73–3.57) 1.44 (0.63–3.29)
Y
N=410
*Adjusted for baseline CD4 count (categorized as above), baseline viral load (dichotomized at 100,000 copies/mL), presence of anemia (categorized as above), and age;
{adjusted for age, baseline viral load, male sex, and presence of anemia;
Yadjusted for baseline CD4 count, age, baseline viral load, and male sex
HR=hazard ratio; CI=confidence interval
doi:10.1371/journal.pone.0001725.t003
Survival after HAART
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died. If true, the finding of underestimation of deaths and bias due
to informative censoring would likely have been more pronounced
than was presented here. In addition, although the data from
Malawi confirm our estimates of deaths among those lost to follow-
up[11], the study was conducted among only approximately 400
adults initiating HAART in 2003 and 2004. As such, results of this
study do not necessarily represent the outcomes that are being
experienced among patients currently enrolled in the IDCC or in
other clinics in Botswana.
Providing data for comparing outcomes after HAART initiation
across study settings is one way epidemiologic studies can
potentially improve HIV patient care. Using such comparisons,
sites with higher mortality or loss to follow-up rates can explore
operational characteristics of sites or biologic or behavioral aspects
of patients with lower rates in order to attempt to identify
procedures or interventions capable of improving patient retention
and survival. To facilitate such investigations, survival rates and
risk factors for death with minimal inherent bias are needed.
Uniform reporting standards have been advocated for randomized
clinical trials[25], for analyses of diagnostic tests[26], and, more
recently, for observational cohort studies[27,28]. Adoption of such
standards with respect to reporting outcomes from observational
cohort studies of HAART use ideally will improve reporting of the
number and percent of patients lost to follow-up after HAART
initiation, thereby facilitating future research efforts into ways to
improve patient care.
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